Department of Pharmacology, ShanXi Medical University, PR China.
J Renin Angiotensin Aldosterone Syst. 2013 Jun;14(2):146-55. doi: 10.1177/1470320312470580. Epub 2012 Dec 21.
The objective of this article is to assess the effects of nebivolol on resistant vascular reactivity, ventricular hypertrophy and the renin-angiotensin system in spontaneously hypertension rats (SHR).
Rats were divided into: SHR treated with nebivolol (8 mg/kg, i.g.)/atenolol(80 mg/kg, i.g.); SHR control group; normotensive Wistar-Kyoto (WKY) control group. Vascular responses to KCl, noradrenaline (NA), endothelin-1 (ET-1), angiotensin II (Ang II), acetylcholine (ACh) and sodium nitroprusside (SNP) were tested on the femoral and renal artery. Left ventricle weight/body weight ratio (LVW/BW) was measured. Ang II and angiotensin-converting enzyme (ACE) activity in plasma and the left ventricle were determined. Plasma renin activity (PRA) was quantified.
Systolic blood pressure was decreased after nebivolol treatment in SHR. Compared with WKY, the contractions to KCl, NA, Ang II and ET-1 were increased in SHR while the relaxation to ACh was impaired. LVW/BW was higher in SHR. Levels of Ang II and ACE activity in plasma and the left ventricle were increased in SHR, but PRA was similar in these groups. Compared with atenolol, nebivolol markedly improved resistant vascular reactivity and decreased LVW/BW and Ang II. But nebivolol had no influence on ACE activity and PRA in SHR.
Nebivolol treatment improved resistant arterial reactivity and reduced left ventricular hypertrophy and Ang II in SHR.
本文旨在评估奈必洛尔对耐药血管反应性、心室肥厚和肾素-血管紧张素系统的影响在自发性高血压大鼠（SHR）中。
将大鼠分为：奈必洛尔（8mg/kg，ig）/阿替洛尔（80mg/kg，ig）治疗的 SHR；SHR 对照组；正常血压的 Wistar-Kyoto（WKY）对照组。检测股动脉和肾动脉对氯化钾（KCl）、去甲肾上腺素（NA）、内皮素-1（ET-1）、血管紧张素 II（Ang II）、乙酰胆碱（ACh）和硝普钠（SNP）的血管反应。测量左心室重量/体重比（LVW/BW）。测定血浆和左心室中 Ang II 和血管紧张素转换酶（ACE）活性。定量血浆肾素活性（PRA）。
与 WKY 相比，奈必洛尔治疗后 SHR 的收缩压降低。与 WKY 相比，SHR 的 KCl、NA、Ang II 和 ET-1 收缩反应增强，而 ACh 舒张反应受损。SHR 的 LVW/BW 较高。SHR 血浆和左心室中 Ang II 和 ACE 活性升高，但这些组之间的 PRA 相似。与阿替洛尔相比，奈必洛尔显著改善了耐药血管反应性，并降低了 LVW/BW 和 Ang II。但奈必洛尔对 SHR 的 ACE 活性和 PRA 没有影响。
奈必洛尔治疗改善了 SHR 的耐药动脉反应性，并减少了左心室肥厚和 Ang II。
